FDA Advances CDISC Dataset JSON Testing as Potential XPT v5 Replacement for Regulatory Submissions

Regulatory affairs teams preparing study data packages for CBER and CDER submissions should note that the format underpinning decades of electronic dossiers is under active evaluation for replacement. FDA, in collaboration with CDISC and PhUSE, has completed preliminary testing of the Dataset JSON message exchange standard as a candidate successor to XPT v5, with initial results described as indicating potential for that role.

The evaluation is not yet concluded. CBER and CDER have confirmed further testing is planned to assess Dataset JSON's capability to support regulatory study data submissions across the full range of submission types. Results will be communicated publicly, and FDA has indicated it will engage relevant stakeholders for input as the process advances. No transition timeline or mandatory adoption date has been announced.

For regulatory operations teams, the practical read is straightforward: existing XPT v5 requirements remain in force under the Study Data Technical Conformance Guide and the Standardized Study Data guidance. Submission packages built to current SDTM and SEND standards, validated against FDA Business Rules v1.5 and Validator Rules v1.6, remain the operative standard. Any shift to Dataset JSON would require updated guidance before affecting submission workflows.

The broader context is worth tracking. Dataset JSON is a structured, modern exchange format designed to address known limitations of the SAS Transport File format that XPT v5 is based on, including file size constraints and data type restrictions that increasingly affect large genomic, real-world data, and continuous monitoring datasets. FDA's existing technical specifications for Next Gen Sequencing, Continuous Glucose Monitoring, and Patient-Reported Outcomes in oncology trials already push against those boundaries.

Regulatory leads managing NDA, BDA, or IND portfolios should monitor the FDA Data Standards Advisory Board and CDISC channels for interim findings, and consider whether internal data transformation pipelines and validation tooling would require reconfiguration if Dataset JSON is formally adopted under a future revision to 21 CFR Part 11-aligned submission standards.

The measurable checkpoint ahead is FDA's publication of further testing results and the opening of a stakeholder input period, both of which will define the practical runway before any format transition becomes a submission-readiness concern.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Study Data Standards Resources page, 2026-05-14.